Mediators of inflammation resolution and vasoactive eicosanoids in gestational diabetes and preeclampsia.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
12
8
2022
medline:
12
10
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
Women with gestational diabetes (GDM) have an increased risk of preeclampsia and postpartum diabetes. Inflammation associates with both GDM and preeclampsia. This study examined specialized proresolving mediators (SPM) that direct inflammation resolution and eicosanoids that are involved in inflammation, in relation to the development of preeclampsia and ongoing postpartum glucose intolerance in GDM. Participants were selected from a prospective study examining the development of preeclampsia in women with GDM. Four groups of age-matched women were studied: GDM ( n = 20), GDM who developed preeclampsia (GDM+PE, n = 21), GDM who remained glucose-intolerant postpartum (GDM+PPIGT, n = 20), or pregnancies with glucose tolerance within the normal range (NGT, n = 21). Measurement of SPM (E-series resolvins and D-series resolvins), SPM pathway intermediates (14-HDHA, 18-HEPE and 17-HDHA), 20-hydroxyeicosatetraenoic acid (20-HETE), and the urinary metabolite of the vasodilator prostacyclin 2,3-dinor-6-Keto-PGF 1α , were made at 28, 32 and 36 weeks gestation and at 6 months postpartum. Compared with GDM, GDM+PE had elevated levels of 20-HETE and the SPM pathway intermediates 14-HDHA, 18-HEPE, 17-HDHA, at 32 weeks, and the SPM RvE1 at 32 and 36 weeks gestation. Compared with NGT and regardless of whether they developed preeclampsia or PPIGT, GDM had lower levels of 2,3-dinor-6-Keto-PGF 1α during pregnancy. Reduced levels of the prostacyclin metabolite 2,3-dinor-6-Keto-PGF 1α may contribute to the increased risk of preeclampsia in women with GDM. The increase in 20-HETE, a vasoconstrictor and mediator of inflammation, and SPM that contribute to inflammation resolution, prior to the onset of preeclampsia require further investigation to clarify their clinical significance.
Identifiants
pubmed: 35950986
doi: 10.1097/HJH.0000000000003253
pii: 00004872-202211000-00016
doi:
Substances chimiques
Eicosanoids
0
Inflammation Mediators
0
Prostaglandins F
0
Prostaglandins I
0
Vasoconstrictor Agents
0
Vasodilator Agents
0
S-(2-(N,N-diisopropylamino)ethyl)isothiourea
142620-95-9
Glucose
IY9XDZ35W2
Dimaprit
ZZQ699148P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2236-2244Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Preeclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 2014; 10:466–480.
Barden AE, Beilin LJ, Ritchie L, Walters BN, Michael C. Does a predisposition to the metabolic syndrome sensitize women to develop preeclampsia? J Hypertens 1999; 17:1307–1315.
McElwain CJ, McCarthy FP, McCarthy CM. Gestational diabetes mellitus and maternal immune dysregulation: what we know so far. Int J Mol Sci 2021; 22:4261.
Barden A, Singh R, Walters BN, Ritchie J, Roberman B, Beilin LJ. Factors predisposing to preeclampsia in women with gestational diabetes. J Hypertens 2004; 22:2371–2378.
Mills JL, DerSimonian R, Raymond E, Morrow JD, Roberts LJ 2nd, Clemens JD, et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA 1999; 282:356–362.
Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids 2004; 70:223–232.
Barden A, Beilin LJ, Ritchie J, Walters BN, Michael CA. Plasma and urinary endothelin1, prostacyclin metabolites and platelet consumption in preeclampsia and essential hypertensive pregnancy. Blood Press 1994; 3:38–46.
Biagi G, De Rosa V, Pelusi G, Scagliarini G, Sani G, Coccheri S. Increased placental production of leukotriene B4 in gestational hypertension. Thromb Res 1990; 60:377–384.
Plenty NL, Faulkner JL, Cotton J, Spencer SK, Wallace K, LaMarca B, Murphy SR. Arachidonic acid metabolites of CYP4A and CYP4F are altered in women with preeclampsia. Prostaglandins Other Lipid Mediat 2018; 136:15–22.
Ishizuka T, Cheng J, Singh H, Vitto MD, Manthati VL, Falck JR, Laniado-Schwartzman M. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther 2008; 324:103–110.
Barden A, Beilin LJ, Ritchie J, Croft KD, Walters BN, Michael CA. Plasma and urinary 8-iso-prostane as an indicator of lipid peroxidation in preeclampsia and normal pregnancy. Clin Sci 1996; 91:711–718.
Barden A, Ritchie J, Walters B, Michael C, Rivera J, Mori T, et al. Study of plasma factors associated with neutrophil activation and lipid peroxidation in preeclampsia. Hypertension 2001; 38:803–808.
Huang LL, Su S, Awale R, Zhang XY, Zhong LL, Tang H. Expression of anti-inflammatory mediator lipoxin A4 and inflammation responsive transcriptive factors NF-kappa B in patients with preeclampsia. Clin Exp Obstet Gynecol 2014; 41:561–566.
Perucci LO, Santos PC, Ribeiro LS, Souza DG, Gomes KB, Dusse LM, Sousa LP. Lipoxin A4 is increased in the plasma of preeclamptic women. Am J Hypertens 2016; 29:1179–1185.
Xu Z, Zhao F, Lin F, Xiang H, Wang N, Ye D, Huang Y. Preeclampsia is associated with a deficiency of lipoxin A4, an endogenous anti-inflammatory mediator. Fertil Steril 2014; 102:282.e4–290.e4.
Serhan CN, Chiang N, Dalli J, Levy BD. Lipid mediators in the resolution of inflammation. Cold Spring Harbor Perspect Biol 2015; 7:a016311.
Spite M, Claria J, Serhan CN. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab 2014; 19:21–36.
Isobe Y, Arita M, Matsueda S, Iwamoto R, Fujihara T, Nakanishi H, et al. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem 2012; 287:10525–10534.
Barden AE, Mas E, Mori TA. n-3 Fatty acid supplementation and proresolving mediators of inflammation. Curr Opin Lipidol 2016; 27:26–32.
Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin Immunol 2015; 27:200–215.
Jones ML, Mark PJ, Keelan JA, Barden A, Mas E, Mori TA, Waddell BJ. Maternal dietary omega-3 fatty acid intake increases resolvin and protectin levels in the rat placenta. J Lipid Res 2013; 54:2247–2254.
Keelan JA, Mas E, D’Vaz N, Dunstan JA, Li S, Barden AE, et al. Effects of maternal n-3 fatty acid supplementation on placental cytokines, pro-resolving lipid mediators and their precursors. Reproduction 2015; 149:171–178.
Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, Oats J, et al. The detection, investigation and management of hypertension in pregnancy: executive summary. Aust New Zeal J Obstet Gynaecol 2000; 40:133–138.
Franx A, van der Post JA, Elfering IM, Veerman DP, Merkus HM, Boer K, van Montfrans GA. Validation of automated blood pressure recording in pregnancy. Brit J Obstet Gynaecol 1994; 101:66–69.
Friedewald WT, Fredrickson DS, Levy RI. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18:499–502.
Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23:57–63.
Barden A, Mas E, Croft KD, Phillips M, Mori TA. Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation. J Lipid Res 2014; 55:2401–2407.
Barden A, Phillips M, Shinde S, Corcoran T, Mori TA. The effects of perioperative dexamethasone on eicosanoids and mediators of inflammation resolution: A sub-study of the PADDAG trial. Prostaglandins Leukot Essent Fatty Acids 2021; 173:102334.
Montoro MN, Kjos SL, Chandler M, Peters RK, Xiang AH, Buchanan TA. Insulin resistance and preeclampsia in gestational diabetes mellitus. Diabetes Care 2005; 28:1995–2000.
Barden A, Beilin LJ, Burke V, Ritchie J, Michael CA, Walters BN. Relationships between plasma endothelin and prostacyclin in normal and preeclamptic pregnancy. Hypertens Pregnancy 1996; 15:25–38.
Gangadhariah MH, Luther JM, Garcia V, Paueksakon P, Zhang MZ, Hayward SW, et al. Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy. J Am Soc Nephrol 2015; 26:597–610.
Sedlakova L, Kikerlova S, Huskova Z, Cervenkova L, Chabova VC, Zicha J, et al. 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Biosci Rep 2018; 38: BSR20171496.
Gilani A, Agostinucci K, Hossain S, Pascale JV, Garcia V, Adebesin AM, et al. 20-HETE interferes with insulin signaling and contributes to obesity-driven insulin resistance. Prostaglandins Other Lipid Mediat 2021; 152:106485.
Bello NA, Woolley JJ, Cleary KL, Falzon L, Alpert BS, Oparil S, et al. Accuracy of blood pressure measurement devices in pregnancy: a systematic review of validation studies. Hypertension 2018; 71:326–335.
Innes KE, Wimsatt JH. Pregnancy-induced hypertension and insulin resistance: evidence for a connection. Acta Obstet Gynecol Scand 1999; 78:263–284.
Abundis EM, Ortiz MG, Galvan AQ, Ferrannini E. Hyperinsulinemia in glucose-tolerant women with preeclampsia - a controlled study. Am J Hypertens 1996; 9:610–614.
Lorentzen B, Birkeland KI, Endresen MJ, Henriksen T. Glucose intolerance in women with preeclampsia. Acta Obstet Gynecol Scand 1998; 77:22–27.
Barden A, Graham D, Beilin LJ, Ritchie J, Baker R, Walters BN, et al. Neutrophil CD11B expression and neutrophil activation in preeclampsia. Clin Sci 1997; 92:37–44.
Mackay VA, Huda SS, Stewart FM, Tham K, McKenna LA, Martin I, et al. Preeclampsia is associated with compromised maternal synthesis of long-chain polyunsaturated fatty acids, leading to offspring deficiency. Hypertension 2012; 60:1078–1085.
Sima C, Paster B, Van Dyke TE. Function of pro-resolving lipid mediator Resolvin E1 in type 2 diabetes. Crit Rev Immunol 2018; 38:343–365.
Wang DY, Ding WJ, Xu SQ, Chen HT, Liu B, Wang ZL. The relationship between total cholesterol and postpartum impaired glucose tolerance in women with gestational diabetes mellitus. Lipids Health Dis 2020; 19:142.
Pendzialek SM, Schindler M, Plosch T, Gurke J, Haucke E, Hecht S, et al. Cholesterol metabolism in rabbit blastocysts under maternal diabetes. Reprod Fertil Dev 2017; 29:1921–1931.